Volume 20, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Yomesan—N-(2′-chlor-4′-nitrophenyl)-5 chlorsalicylamid—was ineffective in 10 children with infections who were treated with a single dose of 100 mg per kg of body weight. On the other hand, at least 90% of 62 children who received 40 to 80 mg per kg per day for 5 days were cured as evidenced by negative stool examinations performed weekly or biweekly for 10 to 12 weeks after treatment. Nine untreated children used as controls and similarly examined remained positive throughout the observation period. No objective signs of intolerance or toxicity were noted. In view of the world-wide reports of the efficacy and safety of Yomesan (niclosamide) in the treatment of infections and its extensive use in many parts of the world, we suggest that this drug be made available in the United States.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...


Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error